1. Home
  2. VVPR vs CTSO Comparison

VVPR vs CTSO Comparison

Compare VVPR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoPower International PLC

VVPR

VivoPower International PLC

HOLD

Current Price

$3.20

Market Cap

40.2M

Sector

Utilities

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.64

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVPR
CTSO
Founded
2014
1997
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Power Generation
Medical/Dental Instruments
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
45.9M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
VVPR
CTSO
Price
$3.20
$0.64
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
498.2K
114.9K
Earning Date
09-02-2023
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$61,000.00
$36,979,520.00
Revenue This Year
N/A
$9.51
Revenue Next Year
N/A
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
281.25
23.89
52 Week Low
$0.62
$0.60
52 Week High
$8.88
$1.61

Technical Indicators

Market Signals
Indicator
VVPR
CTSO
Relative Strength Index (RSI) 55.73 40.33
Support Level $2.59 $0.60
Resistance Level $3.20 $0.76
Average True Range (ATR) 0.26 0.06
MACD 0.12 -0.01
Stochastic Oscillator 91.38 16.74

Price Performance

Historical Comparison
VVPR
CTSO

About VVPR VivoPower International PLC

Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: